New breakthroughs driving acute kidney disease research
As new knowledge about Acute kidney injury is uncovered, a global, multicentre clinical trial works to revolutionise the treatment of renal failure
Acute kidney injury (AKI) - the sudden loss of renal function - places an increasing burden on health systems around the world and in many instances leads to further, often chronic, complications for individuals.
The causes of and contributors to AKI are various, including dehydration, sepsis, systemic disease, kidney injury and heart failure. The onset of AKI after surgery is associated with higher mortality, and evidence highlights increasing co-morbidity between AKI and obesity and chronic diseases, such as diabetes.
The underlying causes of AKI dictate the clinical management of the disease. Refining the diagnosis and best treatment of AKI remains a clinical and research priority, as well as identifying hospitalised patients at greatest risk of AKI.
Recent research has uncovered four chromosomal gene variants associated with increased risk for AKI, and calls for further examination of appropriate approaches to management of AKI.
Other recent data suggests glucose-lowering agents used in the treatment of type 2 diabetes may be effective in reducing the risk of kidney failure in patients with diabetes.
Active clinical trial
One such drug, Canagliflozin, is the focus of CREDENCE, a global, multicentre clinical trial determining whether it has a protective effect in reducing the advancement of renal impairment. CREDENCE involves scientific leadership from The George Institute and George Clinical, and if successful this trial will lead to dramatic improvements in the clinical care of people with diabetes and high risk of kidney failure.
George Clinicala leading Asia-Pacific CRO, has one of the most substantial renal study site networks in Asia, with over 60,000 participants to date. Previous successful kidney trials led by George Clinical have successfully examined intensive dialysis and renal replacement therapy.